Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, low concentrations of DMSO were found to decrease androgen receptor expression and inhibit the migration of prostate cancer cells, suggesting potential as an anticancer therapy.

This study found that patients with alopecia areata had significantly higher systemic immune-inflammation index levels compared to healthy controls, regardless of the disease's severity.

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.

This discussion proposes a model to incorporate patients with hormone-resistant prostate cancer into the existing framework by redefining hormone resistance and exploring new therapeutic approaches.

This review discusses how the HSD3B1(1245C) genotype may impact androgen physiology and the progression of castration-resistant prostate cancer, and does not report new experimental results.

This study developed and validated a mass spectrometric method to measure hydroxy-androgens in serum, which aids in understanding androgen synthesis in castration resistant prostate cancer.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

In this study, researchers reported that the SHBG +5790 G>A polymorphism was associated with an increased risk of developing resistance to hormonal castration in advanced prostate cancer patients.

This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

This review discusses the relationship between polycystic ovary syndrome and inflammation, highlighting various inflammatory markers, but reports no new clinical results.

This study found that reduced expression of CD200R1 on monocyte-derived macrophages in rheumatoid arthritis patients was significantly associated with higher disease severity and an imbalance in Th17/Treg cells.

This systematic review identified several factors contributing to increased cardiovascular risk in women with polycystic ovary syndrome, including insulin resistance, obesity, inflammation markers, and microbiota alterations linked to elevated trimethylamine-N-oxide levels.

This study found that patients with alopecia areata had higher levels of oxidative stress markers and lower antioxidant enzyme activity compared to healthy controls.

In this randomized trial, lupus patients taking daily 200 μg selenium supplements for eight weeks showed significant improvements in metabolic markers like CRP, ESR, MDA, and GPX, as well as reduced clinical symptoms such as arthritis and alopecia, compared to those receiving a placebo.

This study found that CRP levels were elevated in alopecia areata patients, with an inverse linear association between serum vitamin D and CRP levels specifically noted in ophiasis AA.

This study found that lower GPX4 mRNA levels in polymorphonuclear neutrophils of systemic lupus erythematosus patients were negatively associated with disease activity and serological markers, suggesting a diagnostic value for GPX4 mRNA.

This study evaluated the effects of metformin, ethinyl estradiol/cyproterone acetate (EE/SA), and their combination on carotid intima-media thickness and various cardiovascular markers in patients with polycystic ovary syndrome.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This study provides evidence that a pragmatic lifestyle intervention combining exercise and dietary advice may improve health outcomes in men with advanced prostate cancer receiving androgen suppression therapy.

This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.

This review discusses the diagnosis, management, and treatment options for peripheral arterial disease and does not report new clinical findings; the authors emphasize the need for early diagnosis and comprehensive management.

This study found that higher levels of AR expression are linked to a decreased risk of severe COVID-19 in females, and identified ACE2, MX1, and TMPRSS2 as important molecular markers for COVID-19 management.

This case report documents a 44-year-old female with Down's syndrome who was diagnosed with both rheumatoid arthritis and gouty arthritis, highlighting her specific clinical presentation and treatment regimen.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

In this study, researchers estimated that 80% of patients infected with SARS-CoV-2 experienced at least one long-term symptom, with fatigue being the most common.